FR2791348B1 - POLYPEPTIDE Npt2B - Google Patents

POLYPEPTIDE Npt2B

Info

Publication number
FR2791348B1
FR2791348B1 FR0001438A FR0001438A FR2791348B1 FR 2791348 B1 FR2791348 B1 FR 2791348B1 FR 0001438 A FR0001438 A FR 0001438A FR 0001438 A FR0001438 A FR 0001438A FR 2791348 B1 FR2791348 B1 FR 2791348B1
Authority
FR
France
Prior art keywords
npt2b
polypeptide
polypeptide npt2b
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0001438A
Other languages
English (en)
Other versions
FR2791348A1 (fr
Inventor
Paul David Cannon
Suryanarayana Sankurati
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of FR2791348A1 publication Critical patent/FR2791348A1/fr
Application granted granted Critical
Publication of FR2791348B1 publication Critical patent/FR2791348B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR0001438A 1999-02-09 2000-02-04 POLYPEPTIDE Npt2B Expired - Fee Related FR2791348B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11932199P 1999-02-09 1999-02-09

Publications (2)

Publication Number Publication Date
FR2791348A1 FR2791348A1 (fr) 2000-09-29
FR2791348B1 true FR2791348B1 (fr) 2007-10-05

Family

ID=22383760

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0001438A Expired - Fee Related FR2791348B1 (fr) 1999-02-09 2000-02-04 POLYPEPTIDE Npt2B

Country Status (14)

Country Link
US (3) US6380374B1 (fr)
JP (2) JP2000245488A (fr)
AT (1) AT411759B (fr)
AU (1) AU741170B2 (fr)
BE (1) BE1014389A5 (fr)
CA (1) CA2296178C (fr)
CH (1) CH694588A5 (fr)
DE (1) DE10004815B4 (fr)
FR (1) FR2791348B1 (fr)
GB (1) GB2348645A (fr)
IE (1) IE20000117A1 (fr)
IT (1) ITMI20000200A1 (fr)
NL (1) NL1014331C2 (fr)
SE (1) SE523043C2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2633413C (fr) * 2001-06-20 2012-08-21 Genentech, Inc. Compositions et procedes destines au diagnostic et au traitement de tumeurs
IL159722A0 (en) * 2001-07-10 2004-06-20 Oligos Etc Inc Pharmaceutical compositions containing oligonucleotides
US20050004348A1 (en) * 2002-12-23 2005-01-06 Miyamoto Ken-Ichi Novel type II Na/Pi cotransporters and type II Na/Pi cotransporter expression regulatory factors
BRPI0716319A8 (pt) * 2006-10-25 2019-02-05 Aovatechnologies Inc método para reduzir a absorção de fosfato em um indivíduo animal humano ou não-humano correndo o risco de desenvolver ou que desenvolveu hiperfosfatomia e método para reduzir os efeitos colaterais da terapia de vitamina d em um ser humano
JP5701504B2 (ja) * 2006-10-26 2015-04-15 ウィスコンシン アルムニ リサーチ ファンデイション リン酸塩吸収の低減方法
NZ599707A (en) * 2009-11-30 2014-07-25 Genentech Inc Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 )
JP7137474B2 (ja) 2016-03-15 2022-09-14 メルサナ セラピューティクス，インコーポレイティド ＮａＰｉ２ｂ標的化抗体－薬物コンジュゲート及びその使用方法
BR112020005390A2 (pt) 2017-09-20 2020-09-29 Mersana Therapeutics, Inc. composições e métodos para prever a resposta à terapia direcionada ao napi2b
CA3109790A1 (fr) 2018-08-17 2020-02-20 Mersana Therapeutics, Inc. Conjugues anticorps-medicament polymere ciblant napi2b et leurs procedes d'utilisation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985604A (en) * 1997-02-24 1999-11-16 Incyte Pharmaceuticals, Inc. Human sodium-dependent phosphate cotransporter
US6319688B1 (en) * 1997-04-28 2001-11-20 Smithkline Beecham Corporation Polynucleotide encoding human sodium dependent phosphate transporter (IPT-1)

Also Published As

Publication number Publication date
JP2003325189A (ja) 2003-11-18
AT411759B (de) 2004-05-25
SE523043C2 (sv) 2004-03-23
NL1014331A1 (nl) 2000-08-10
US7368530B2 (en) 2008-05-06
AU741170B2 (en) 2001-11-22
SE0000375D0 (sv) 2000-02-07
DE10004815B4 (de) 2010-01-21
DE10004815A1 (de) 2000-10-12
CA2296178C (fr) 2004-05-04
FR2791348A1 (fr) 2000-09-29
CH694588A5 (de) 2005-04-15
BE1014389A5 (fr) 2003-10-07
US20020156266A1 (en) 2002-10-24
SE0000375L (sv) 2000-08-10
CA2296178A1 (fr) 2000-08-09
GB0002665D0 (en) 2000-03-29
ITMI20000200A0 (it) 2000-02-08
US20090170122A1 (en) 2009-07-02
GB2348645A (en) 2000-10-11
JP2000245488A (ja) 2000-09-12
NL1014331C2 (nl) 2003-06-03
US6380374B1 (en) 2002-04-30
US7803562B2 (en) 2010-09-28
IE20000117A1 (en) 2000-09-06
ITMI20000200A1 (it) 2001-08-08
AU1497900A (en) 2000-08-31
ATA1972000A (de) 2003-10-15

Similar Documents

Publication Publication Date Title
NO982097L (no) Peptider
NO982098D0 (no) Peptider
NO2010019I2 (no) 6-per-deoksy-6-per-(2-karboksetyl)tio-y-cyklodextrin
DE122007000064I2 (de) Erythropoietinkonjugate
DE19983871T1 (de) Fönvorrichtung
DE10084676T1 (de) Einmallanzettvorrichtung
ATA51899A (de) Handstempel
DE69920011D1 (de) Rekombinanter venezolanische-equine-pferdeenzephalitis-virusimpstoff
ATE357433T1 (de) 4-pyrimidinyl-n-acyl-l-phenylanine
ATE297895T1 (de) 4-pyridinyl-n-acyl-l-phenylalanine
DE50007953D1 (de) Beleuchtungsanordung
DE50008613D1 (de) Sicherungsring
DE50000805D1 (de) Aufsitzspanner
DE50006899D1 (de) Antistatikum
DE10085008T1 (de) Oberflächenbehandlungsdüse
FR2791348B1 (fr) POLYPEPTIDE Npt2B
DE50003660D1 (de) Diacylhydrazinderivate
DE50006013D1 (de) Anschlagpuffer
DE50003259D1 (de) Textilie
DK1230369T3 (da) Polypeptidhormon phosphatonin
DE50008429D1 (de) Kraftstofffraktioniereinrichtung
DE50001640D1 (de) Nahfeldoptische untersuchungsvorrichtung
NO20013933D0 (no) Peptider
DE10082008D2 (de) Ausbeulgerät
DE50006829D1 (de) Benzoylpyridazine

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 18

PLFP Fee payment

Year of fee payment: 19

ST Notification of lapse

Effective date: 20191005